Prima BioMed (NASDAQ:IMMP) Research Coverage Started at Citizens Jmp

Citizens Jmp initiated coverage on shares of Prima BioMed (NASDAQ:IMMP) in a research note released on Monday morning,Benzinga reports. The firm issued a market outperform rating and a $10.00 price target on the biotechnology company’s stock.

Several other research firms have also recently weighed in on IMMP. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prima BioMed in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Prima BioMed from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Prima BioMed Stock Down 0.4%

IMMP stock opened at $2.79 on Monday. Prima BioMed has a fifty-two week low of $1.32 and a fifty-two week high of $3.53. The firm’s 50-day simple moving average is $2.89 and its 200 day simple moving average is $2.22.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC lifted its position in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. 2.32% of the stock is currently owned by institutional investors.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.